[ad_1]
Portugal will receive 2 million more doses of Pfizer vaccine than originally planned, after the European Union announced the purchase of 100 million additional doses of that vaccine against Covid-19, according to a news from Antena 1.
According to public radio, in addition to the approximately 1.2 million doses that the country was to receive at the end of the first quarter of 2021, about 2 million more doses of the Pfizer vaccine will be added to the Portuguese order.
On Tuesday, the President of the European Commission, Ursula von der Leyen, had announced Whereas the European Union has reinforced the request made to Pfizer, buying more than 100 million doses and raise the total number of doses purchased by the European bloc from pharmaceutical products to 300 million.
We decided to take an additional 100 million doses of the #BioNTech /@Pfizer vaccine, which is already being used to vaccinate people across the EU.
Therefore, we will have 300 million doses of this vaccine, which has been evaluated as safe and effective.
More vaccines will follow!
– Ursula von der Leyen (@vonderleyen) December 29, 2020
The Pfizer vaccine was the first to be approved by the European Medicines Agency and is already being distributed throughout Europe, including Portugal.
After the arrival in Portugal of a first batch of 9,750 vaccines, a second batch has already been delivered, with more than 70,000 doses, which are being used for the current vaccination process of healthcare professionals.
According to the first accounts, more than 300 thousand doses will have arrived in January and, at the end of March, A total of 487,500 doses of the vaccine were expected. from Pfizer, but this number is now expected to rise with the new European Union purchase.
The Pfizer vaccine is one of many that the European Union has acquired from pharmaceutical companies, to which should be added the vaccines from AstraZeneca, Sanofi-GSK, Johnson and Johnson, CureVac and Moderna. This Wednesday, the United Kingdom approved the AstraZeneca vaccine, which has not yet received authorization for use in the European Union.
[ad_2]
